Report cover image

Global Inactivated Influenza Virus Vaccine Market Analysis and Forecast 2025-2031

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 202 Pages
SKU # APRC20361158

Description

Summary

According to APO Research, The global Inactivated Influenza Virus Vaccine market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Inactivated Influenza Virus Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Inactivated Influenza Virus Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Inactivated Influenza Virus Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Inactivated Influenza Virus Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Inactivated Influenza Virus Vaccine include CSL, Zhejiang Tian Yuan Biopharmaceutical Co., Ltd, Changchun Institute of Biological Products Co., Ltd, Shanghai Institute of Biological Products Co., Ltd, Johnson & Johnson, Mylan, Lanzhou Institute of Biological Products Co., Ltd, Jiangsu Kangrun Biotechnology Co., Ltd and Jiangsu Jindik Biotechnology Co., Ltd, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Inactivated Influenza Virus Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Inactivated Influenza Virus Vaccine, also provides the sales of main regions and countries. Of the upcoming market potential for Inactivated Influenza Virus Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Inactivated Influenza Virus Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Inactivated Influenza Virus Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Inactivated Influenza Virus Vaccine sales, projected growth trends, production technology, application and end-user industry.

Inactivated Influenza Virus Vaccine Segment by Company

CSL
Zhejiang Tian Yuan Biopharmaceutical Co., Ltd
Changchun Institute of Biological Products Co., Ltd
Shanghai Institute of Biological Products Co., Ltd
Johnson & Johnson
Mylan
Lanzhou Institute of Biological Products Co., Ltd
Jiangsu Kangrun Biotechnology Co., Ltd
Jiangsu Jindik Biotechnology Co., Ltd
Pfizer
Hualan Bio Vaccines Co., Ltd
GSK
Dalian Yalifeng Biopharmaceutical Co., Ltd
Beijing Kexing Biological Products Co., Ltd
Emmi Chengxin Biopharmaceutical Co., Ltd
AstraZeneca
Sanofi Pasteur
Inactivated Influenza Virus Vaccine Segment by Type

Whole Virus Vaccine
Subunit Vaccine
Inactivated Influenza Virus Vaccine Segment by Application

Hospital
Clinic
Inactivated Influenza Virus Vaccine Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Inactivated Influenza Virus Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Inactivated Influenza Virus Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Inactivated Influenza Virus Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Sales (consumption), revenue of Inactivated Influenza Virus Vaccine in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 4: Detailed analysis of Inactivated Influenza Virus Vaccine manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Inactivated Influenza Virus Vaccine sales, revenue, price, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.
Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.
Chapter 10: China type, by application, sales, and revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.
Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 14: The main concluding insights of the report.

Table of Contents

202 Pages
1 Market Overview
1.1 Product Definition
1.2 Inactivated Influenza Virus Vaccine Market by Type
1.2.1 Global Inactivated Influenza Virus Vaccine Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Whole Virus Vaccine
1.2.3 Subunit Vaccine
1.3 Inactivated Influenza Virus Vaccine Market by Application
1.3.1 Global Inactivated Influenza Virus Vaccine Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Inactivated Influenza Virus Vaccine Market Dynamics
2.1 Inactivated Influenza Virus Vaccine Industry Trends
2.2 Inactivated Influenza Virus Vaccine Industry Drivers
2.3 Inactivated Influenza Virus Vaccine Industry Opportunities and Challenges
2.4 Inactivated Influenza Virus Vaccine Industry Restraints
3 Global Market Growth Prospects
3.1 Global Inactivated Influenza Virus Vaccine Revenue Estimates and Forecasts (2020-2031)
3.2 Global Inactivated Influenza Virus Vaccine Revenue by Region
3.2.1 Global Inactivated Influenza Virus Vaccine Revenue by Region: 2020 VS 2024 VS 2031
3.2.2 Global Inactivated Influenza Virus Vaccine Revenue by Region (2020-2025)
3.2.3 Global Inactivated Influenza Virus Vaccine Revenue by Region (2026-2031)
3.2.4 Global Inactivated Influenza Virus Vaccine Revenue Market Share by Region (2020-2031)
3.3 Global Inactivated Influenza Virus Vaccine Sales Estimates and Forecasts 2020-2031
3.4 Global Inactivated Influenza Virus Vaccine Sales by Region
3.4.1 Global Inactivated Influenza Virus Vaccine Sales by Region: 2020 VS 2024 VS 2031
3.4.2 Global Inactivated Influenza Virus Vaccine Sales by Region (2020-2025)
3.4.3 Global Inactivated Influenza Virus Vaccine Sales by Region (2026-2031)
3.4.4 Global Inactivated Influenza Virus Vaccine Sales Market Share by Region (2020-2031)
3.5 US & Canada & Mexico
3.6 Europe
3.7 China
3.8 Asia (Excluding China)
3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
4.1 Global Inactivated Influenza Virus Vaccine Revenue by Manufacturers
4.1.1 Global Inactivated Influenza Virus Vaccine Revenue by Manufacturers (2020-2025)
4.1.2 Global Inactivated Influenza Virus Vaccine Revenue Market Share by Manufacturers (2020-2025)
4.1.3 Global Inactivated Influenza Virus Vaccine Manufacturers Revenue Share Top 10 and Top 5 in 2024
4.2 Global Inactivated Influenza Virus Vaccine Sales by Manufacturers
4.2.1 Global Inactivated Influenza Virus Vaccine Sales by Manufacturers (2020-2025)
4.2.2 Global Inactivated Influenza Virus Vaccine Sales Market Share by Manufacturers (2020-2025)
4.2.3 Global Inactivated Influenza Virus Vaccine Manufacturers Sales Share Top 10 and Top 5 in 2024
4.3 Global Inactivated Influenza Virus Vaccine Sales Price by Manufacturers (2020-2025)
4.4 Global Inactivated Influenza Virus Vaccine Key Manufacturers Ranking, 2023 VS 2024 VS 2025
4.5 Global Inactivated Influenza Virus Vaccine Key Manufacturers Manufacturing Sites & Headquarters
4.6 Global Inactivated Influenza Virus Vaccine Manufacturers, Product Type & Application
4.7 Global Inactivated Influenza Virus Vaccine Manufacturers' Establishment Date
4.8 Market Competitive Analysis
4.8.1 Global Inactivated Influenza Virus Vaccine Market CR5 and HHI
4.8.2 2024 Inactivated Influenza Virus Vaccine Tier 1, Tier 2, and Tier 3
5 Inactivated Influenza Virus Vaccine Market by Type
5.1 Global Inactivated Influenza Virus Vaccine Revenue by Type
5.1.1 Global Inactivated Influenza Virus Vaccine Revenue by Type (2020 VS 2024 VS 2031)
5.1.2 Global Inactivated Influenza Virus Vaccine Revenue by Type (2020-2031) & (US$ Million)
5.1.3 Global Inactivated Influenza Virus Vaccine Revenue Market Share by Type (2020-2031)
5.2 Global Inactivated Influenza Virus Vaccine Sales by Type
5.2.1 Global Inactivated Influenza Virus Vaccine Sales by Type (2020 VS 2024 VS 2031)
5.2.2 Global Inactivated Influenza Virus Vaccine Sales by Type (2020-2031) & (K Units)
5.2.3 Global Inactivated Influenza Virus Vaccine Sales Market Share by Type (2020-2031)
5.3 Global Inactivated Influenza Virus Vaccine Price by Type
6 Inactivated Influenza Virus Vaccine Market by Application
6.1 Global Inactivated Influenza Virus Vaccine Revenue by Application
6.1.1 Global Inactivated Influenza Virus Vaccine Revenue by Application (2020 VS 2024 VS 2031)
6.1.2 Global Inactivated Influenza Virus Vaccine Revenue by Application (2020-2031) & (US$ Million)
6.1.3 Global Inactivated Influenza Virus Vaccine Revenue Market Share by Application (2020-2031)
6.2 Global Inactivated Influenza Virus Vaccine Sales by Application
6.2.1 Global Inactivated Influenza Virus Vaccine Sales by Application (2020 VS 2024 VS 2031)
6.2.2 Global Inactivated Influenza Virus Vaccine Sales by Application (2020-2031) & (K Units)
6.2.3 Global Inactivated Influenza Virus Vaccine Sales Market Share by Application (2020-2031)
6.3 Global Inactivated Influenza Virus Vaccine Price by Application
7 Company Profiles
7.1 CSL
7.1.1 CSL Comapny Information
7.1.2 CSL Business Overview
7.1.3 CSL Inactivated Influenza Virus Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.1.4 CSL Inactivated Influenza Virus Vaccine Product Portfolio
7.1.5 CSL Recent Developments
7.2 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd
7.2.1 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Comapny Information
7.2.2 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Business Overview
7.2.3 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.2.4 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
7.2.5 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Recent Developments
7.3 Changchun Institute of Biological Products Co., Ltd
7.3.1 Changchun Institute of Biological Products Co., Ltd Comapny Information
7.3.2 Changchun Institute of Biological Products Co., Ltd Business Overview
7.3.3 Changchun Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.3.4 Changchun Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
7.3.5 Changchun Institute of Biological Products Co., Ltd Recent Developments
7.4 Shanghai Institute of Biological Products Co., Ltd
7.4.1 Shanghai Institute of Biological Products Co., Ltd Comapny Information
7.4.2 Shanghai Institute of Biological Products Co., Ltd Business Overview
7.4.3 Shanghai Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.4.4 Shanghai Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
7.4.5 Shanghai Institute of Biological Products Co., Ltd Recent Developments
7.5 Johnson & Johnson
7.5.1 Johnson & Johnson Comapny Information
7.5.2 Johnson & Johnson Business Overview
7.5.3 Johnson & Johnson Inactivated Influenza Virus Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.5.4 Johnson & Johnson Inactivated Influenza Virus Vaccine Product Portfolio
7.5.5 Johnson & Johnson Recent Developments
7.6 Mylan
7.6.1 Mylan Comapny Information
7.6.2 Mylan Business Overview
7.6.3 Mylan Inactivated Influenza Virus Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.6.4 Mylan Inactivated Influenza Virus Vaccine Product Portfolio
7.6.5 Mylan Recent Developments
7.7 Lanzhou Institute of Biological Products Co., Ltd
7.7.1 Lanzhou Institute of Biological Products Co., Ltd Comapny Information
7.7.2 Lanzhou Institute of Biological Products Co., Ltd Business Overview
7.7.3 Lanzhou Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.7.4 Lanzhou Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
7.7.5 Lanzhou Institute of Biological Products Co., Ltd Recent Developments
7.8 Jiangsu Kangrun Biotechnology Co., Ltd
7.8.1 Jiangsu Kangrun Biotechnology Co., Ltd Comapny Information
7.8.2 Jiangsu Kangrun Biotechnology Co., Ltd Business Overview
7.8.3 Jiangsu Kangrun Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.8.4 Jiangsu Kangrun Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
7.8.5 Jiangsu Kangrun Biotechnology Co., Ltd Recent Developments
7.9 Jiangsu Jindik Biotechnology Co., Ltd
7.9.1 Jiangsu Jindik Biotechnology Co., Ltd Comapny Information
7.9.2 Jiangsu Jindik Biotechnology Co., Ltd Business Overview
7.9.3 Jiangsu Jindik Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.9.4 Jiangsu Jindik Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
7.9.5 Jiangsu Jindik Biotechnology Co., Ltd Recent Developments
7.10 Pfizer
7.10.1 Pfizer Comapny Information
7.10.2 Pfizer Business Overview
7.10.3 Pfizer Inactivated Influenza Virus Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.10.4 Pfizer Inactivated Influenza Virus Vaccine Product Portfolio
7.10.5 Pfizer Recent Developments
7.11 Hualan Bio Vaccines Co., Ltd
7.11.1 Hualan Bio Vaccines Co., Ltd Comapny Information
7.11.2 Hualan Bio Vaccines Co., Ltd Business Overview
7.11.3 Hualan Bio Vaccines Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.11.4 Hualan Bio Vaccines Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
7.11.5 Hualan Bio Vaccines Co., Ltd Recent Developments
7.12 GSK
7.12.1 GSK Comapny Information
7.12.2 GSK Business Overview
7.12.3 GSK Inactivated Influenza Virus Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.12.4 GSK Inactivated Influenza Virus Vaccine Product Portfolio
7.12.5 GSK Recent Developments
7.13 Dalian Yalifeng Biopharmaceutical Co., Ltd
7.13.1 Dalian Yalifeng Biopharmaceutical Co., Ltd Comapny Information
7.13.2 Dalian Yalifeng Biopharmaceutical Co., Ltd Business Overview
7.13.3 Dalian Yalifeng Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.13.4 Dalian Yalifeng Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
7.13.5 Dalian Yalifeng Biopharmaceutical Co., Ltd Recent Developments
7.14 Beijing Kexing Biological Products Co., Ltd
7.14.1 Beijing Kexing Biological Products Co., Ltd Comapny Information
7.14.2 Beijing Kexing Biological Products Co., Ltd Business Overview
7.14.3 Beijing Kexing Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.14.4 Beijing Kexing Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
7.14.5 Beijing Kexing Biological Products Co., Ltd Recent Developments
7.15 Emmi Chengxin Biopharmaceutical Co., Ltd
7.15.1 Emmi Chengxin Biopharmaceutical Co., Ltd Comapny Information
7.15.2 Emmi Chengxin Biopharmaceutical Co., Ltd Business Overview
7.15.3 Emmi Chengxin Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.15.4 Emmi Chengxin Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
7.15.5 Emmi Chengxin Biopharmaceutical Co., Ltd Recent Developments
7.16 AstraZeneca
7.16.1 AstraZeneca Comapny Information
7.16.2 AstraZeneca Business Overview
7.16.3 AstraZeneca Inactivated Influenza Virus Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.16.4 AstraZeneca Inactivated Influenza Virus Vaccine Product Portfolio
7.16.5 AstraZeneca Recent Developments
7.17 Sanofi Pasteur
7.17.1 Sanofi Pasteur Comapny Information
7.17.2 Sanofi Pasteur Business Overview
7.17.3 Sanofi Pasteur Inactivated Influenza Virus Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.17.4 Sanofi Pasteur Inactivated Influenza Virus Vaccine Product Portfolio
7.17.5 Sanofi Pasteur Recent Developments
8 North America
8.1 North America Inactivated Influenza Virus Vaccine Market Size by Type
8.1.1 North America Inactivated Influenza Virus Vaccine Revenue by Type (2020-2031)
8.1.2 North America Inactivated Influenza Virus Vaccine Sales by Type (2020-2031)
8.1.3 North America Inactivated Influenza Virus Vaccine Price by Type (2020-2031)
8.2 North America Inactivated Influenza Virus Vaccine Market Size by Application
8.2.1 North America Inactivated Influenza Virus Vaccine Revenue by Application (2020-2031)
8.2.2 North America Inactivated Influenza Virus Vaccine Sales by Application (2020-2031)
8.2.3 North America Inactivated Influenza Virus Vaccine Price by Application (2020-2031)
8.3 North America Inactivated Influenza Virus Vaccine Market Size by Country
8.3.1 North America Inactivated Influenza Virus Vaccine Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
8.3.2 North America Inactivated Influenza Virus Vaccine Sales by Country (2020 VS 2024 VS 2031)
8.3.3 North America Inactivated Influenza Virus Vaccine Price by Country (2020-2031)
8.3.4 United States
8.3.5 Canada
9 Europe
9.1 Europe Inactivated Influenza Virus Vaccine Market Size by Type
9.1.1 Europe Inactivated Influenza Virus Vaccine Revenue by Type (2020-2031)
9.1.2 Europe Inactivated Influenza Virus Vaccine Sales by Type (2020-2031)
9.1.3 Europe Inactivated Influenza Virus Vaccine Price by Type (2020-2031)
9.2 Europe Inactivated Influenza Virus Vaccine Market Size by Application
9.2.1 Europe Inactivated Influenza Virus Vaccine Revenue by Application (2020-2031)
9.2.2 Europe Inactivated Influenza Virus Vaccine Sales by Application (2020-2031)
9.2.3 Europe Inactivated Influenza Virus Vaccine Price by Application (2020-2031)
9.3 Europe Inactivated Influenza Virus Vaccine Market Size by Country
9.3.1 Europe Inactivated Influenza Virus Vaccine Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
9.3.2 Europe Inactivated Influenza Virus Vaccine Sales by Country (2020 VS 2024 VS 2031)
9.3.3 Europe Inactivated Influenza Virus Vaccine Price by Country (2020-2031)
9.3.4 Germany
9.3.5 France
9.3.6 U.K.
9.3.7 Italy
9.3.8 Netherlands
10 China
10.1 China Inactivated Influenza Virus Vaccine Market Size by Type
10.1.1 China Inactivated Influenza Virus Vaccine Revenue by Type (2020-2031)
10.1.2 China Inactivated Influenza Virus Vaccine Sales by Type (2020-2031)
10.1.3 China Inactivated Influenza Virus Vaccine Price by Type (2020-2031)
10.2 China Inactivated Influenza Virus Vaccine Market Size by Application
10.2.1 China Inactivated Influenza Virus Vaccine Revenue by Application (2020-2031)
10.2.2 China Inactivated Influenza Virus Vaccine Sales by Application (2020-2031)
10.2.3 China Inactivated Influenza Virus Vaccine Price by Application (2020-2031)
11 Asia (Excluding China)
11.1 Asia Inactivated Influenza Virus Vaccine Market Size by Type
11.1.1 Asia Inactivated Influenza Virus Vaccine Revenue by Type (2020-2031)
11.1.2 Asia Inactivated Influenza Virus Vaccine Sales by Type (2020-2031)
11.1.3 Asia Inactivated Influenza Virus Vaccine Price by Type (2020-2031)
11.2 Asia Inactivated Influenza Virus Vaccine Market Size by Application
11.2.1 Asia Inactivated Influenza Virus Vaccine Revenue by Application (2020-2031)
11.2.2 Asia Inactivated Influenza Virus Vaccine Sales by Application (2020-2031)
11.2.3 Asia Inactivated Influenza Virus Vaccine Price by Application (2020-2031)
11.3 Asia Inactivated Influenza Virus Vaccine Market Size by Country
11.3.1 Asia Inactivated Influenza Virus Vaccine Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
11.3.2 Asia Inactivated Influenza Virus Vaccine Sales by Country (2020 VS 2024 VS 2031)
11.3.3 Asia Inactivated Influenza Virus Vaccine Price by Country (2020-2031)
11.3.4 Japan
11.3.5 South Korea
11.3.6 India
11.3.7 Australia
11.3.8 Taiwan
11.3.9 Southeast Asia
12 South America, Middle East and Africa
12.1 SAMEA Inactivated Influenza Virus Vaccine Market Size by Type
12.1.1 SAMEA Inactivated Influenza Virus Vaccine Revenue by Type (2020-2031)
12.1.2 SAMEA Inactivated Influenza Virus Vaccine Sales by Type (2020-2031)
12.1.3 SAMEA Inactivated Influenza Virus Vaccine Price by Type (2020-2031)
12.2 SAMEA Inactivated Influenza Virus Vaccine Market Size by Application
12.2.1 SAMEA Inactivated Influenza Virus Vaccine Revenue by Application (2020-2031)
12.2.2 SAMEA Inactivated Influenza Virus Vaccine Sales by Application (2020-2031)
12.2.3 SAMEA Inactivated Influenza Virus Vaccine Price by Application (2020-2031)
12.3 SAMEA Inactivated Influenza Virus Vaccine Market Size by Country
12.3.1 SAMEA Inactivated Influenza Virus Vaccine Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
12.3.2 SAMEA Inactivated Influenza Virus Vaccine Sales by Country (2020 VS 2024 VS 2031)
12.3.3 SAMEA Inactivated Influenza Virus Vaccine Price by Country (2020-2031)
12.3.4 Brazil
12.3.5 Argentina
12.3.6 Chile
12.3.7 Colombia
12.3.8 Peru
12.3.9 Saudi Arabia
12.3.10 Israel
12.3.11 UAE
12.3.12 Turkey
12.3.13 Iran
12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
13.1 Inactivated Influenza Virus Vaccine Value Chain Analysis
13.1.1 Inactivated Influenza Virus Vaccine Key Raw Materials
13.1.2 Raw Materials Key Suppliers
13.1.3 Manufacturing Cost Structure
13.1.4 Inactivated Influenza Virus Vaccine Production Mode & Process
13.2 Inactivated Influenza Virus Vaccine Sales Channels Analysis
13.2.1 Direct Comparison with Distribution Share
13.2.2 Inactivated Influenza Virus Vaccine Distributors
13.2.3 Inactivated Influenza Virus Vaccine Customers
14 Concluding Insights
15 Appendix
15.1 Reasons for Doing This Study
15.2 Research Methodology
15.3 Research Process
15.4 Authors List of This Report
15.5 Data Source
15.5.1 Secondary Sources
15.5.2 Primary Sources
15.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.